Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models

ACY-241 is a novel, orally available and selective histone deacetylase (HDAC) 6 inhibitor in Phase 1b clinical development in multiple myeloma (NCT 02400242). Like the structurally related drug ACY-1215 (ricolinostat), ACY-241 has the potential for a substantially reduced side effect profile versus...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Huang, Pengyu, Almeciga-Pinto, Ingrid, Jarpe, Matthew, van Duzer, John H, Mazitschek, Ralph, Yang, Min, Jones, Simon S, Quayle, Steven N
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2016
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5356834/
https://ncbi.nlm.nih.gov/pubmed/27926524
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13738
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi